Recent advances with agents, such as brentuximab vedotin for CD30-positive PTCLs and checkpoint inhibitors for specific PTCL subtypes, have shown considerable potential (28). The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.